Akebia Therapeutics Inc. Common Stock (AKBA)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Akebia as a small commercial-stage biopharma with 194 employees and products for kidney disease, but the supplied figures do not show a durable moat. Revenue was $49.1 million in fiscal Q2 2026 (quarter ended 2026-06-30), below $62.5 million in fiscal Q2 2025; FY2025 revenue was $236.2 million, yet net income was -$5.3 million. The company has lost money in each of the last four years, and FairStock's Lynch category is none for that reason. Financial health is the weak link: FairStock's debt-to-equity is 7.96, Altman Z-score is -6.19, and ROE is -109.38%. The latest quarter had a net loss of $8.9 million and diluted EPS of -$0.03. FY2024 and FY2023 net losses were -$69.4 million and -$51.9 million, so the recent loss is smaller but not gone. Valuation is not a Graham bargain at the $0.64 close on 2026-10-26: FairStock puts P/E at -5.37 and P/B at 7.16, with a FairStock score of 53/100. The one offset is cash generation: trailing twelve-month free cash flow was $29.5 million, a 16.5% FCF yield on a $178.5 million market cap. I would need evidence that this cash flow is durable and that revenue stops shrinking before calling the business healthy. Growth has been erratic, and the high leverage leaves little room for disappointment.

In plain English: Akebia Therapeutics is a small drugmaker focused on kidney disease treatments. The business looks weak: it lost money in each of the last four years, and in the June 2026 quarter revenue was $49.1 million with a net loss of $8.9 million. At $0.64, the price does not look cheap compared with its accounting value and earnings, though it generated $29.5 million of cash after running and investing in the business over the past year.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer